Earlier in June 2026, the US Food and Drug Administration posted a Class II, firm-initiated recall of 9,750 Boston Scientific ...

BTIG analysts remain high on Boston Scientific (NYSE:BSX) following meetings with the company's management this week.

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Boston Scientific (BSX) stock has been under pressure ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q2 2024 results on Wednesday, July 24. We expect the company to report revenues and earnings in line with the consensus estimates. A rise in ...

Boston Scientific holds a 91% market share in Watchman but has experienced a decline in standalone procedures, partly attributed to competitive pressures and workflow issues. In electrophysiology, ...

May 27 (Reuters) - Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after ‌the medical device maker flagged declining usage of its heart disease ‌device.

17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...

Boston Scientific’s BSX Structural Heart franchise continues to gain momentum, driven by the robust performance of the WATCHMAN left atrial appendage closure (LAAC) platform. WATCHMAN is the global ...